When was Semmatx.com founded?

Semmatx.com was founded in 2014.

Where does Semmatx.com rank among its competitors?

Semmatx.com ranks 23rd amongst 22 active competitors, of which 6 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Wuhan Ruijian Pharmaceutical Technology, which secured $31M in Jun, 2026.

Who are the top competitors of Semmatx.com?

Semmatx.com's top competitors include Regenxbio, Perceive Bio and Wuhan Ruijian Pharmaceutical Technology. Among them, Wuhan Ruijian Pharmaceutical Technology secured the most recent funding round in June, 2026.

Semmatx.com - 2026 Company Profile, Funding & Competitors

Company Details

Developer of stem cell therapies to treat patients with diabetes. This organization focuses on regenerative medicine to provide functional cures for individuals suffering from metabolic conditions. The research involves creating specialized cells to restore natural insulin production. Following the development of these therapeutic approaches, the entity was integrated into a larger pharmaceutical organization to continue advancing clinical progress.

Key Metrics

Founded Year

2014

Stage

Funding Raised

Investors

F-Prime Capital

Ranked

23^rd among 23 competitors

Similar Companies

Regenxbio & 20 more

View Semmatx.com's full profile

Semmatx.com is a funded company. Semmatx.com has 1 institutional investor.

View details of Semmatx.com's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Semmatx.com include Regenxbio, Perceive Bio and Wuhan Ruijian Pharmaceutical Technology. Here is the list of Top 10 competitors of Semmatx.com, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	67/100
2nd	Perceive Bio 2021, San Francisco (United States), Series B	Developer of therapeutics to treat diabetes and eye diseases	$78M	Johnson & Johnson Innovation, Deerfield & 4 others	55/100
3rd	Wuhan Ruijian Pharmaceutical Technology 2017, Wuhan (China), Series C	Developer of cell therapies to treat neurological and ophthalmological diseases	$71M	NLVC, Fortune Capital & 3 others	51/100
4th	veriNOS pharmaceuticals 1998, Wurzburg (Germany), Series G	Developer of therapeutics for retina and brain diseases	$62.7M	HeidelbergCapital, Entrepreneurs Fund & 10 others	42/100
5th	OcuTerra Therapeutics 2020, Boston (United States), Deadpooled	Developer of eye drop to treat diabetic eye disease	$40.2M	Hambro Perks, Salica Investments & 1 others	37/100
6th	ESBATech 1998, Zurich (Switzerland), Acquired	Developer of antibody-based therapeutics for ophthalmic diseases	$63M	HBM Healthcare Investments, HBM Partners & 5 others	37/100
7th	Ocugenix 2015, Pittsburgh (United States), Seed	Developer of therapeutics for ocular diseases	$100K	Innovation Works, Mountain State Capital	31/100
8th	MingSight 2009, San Diego (United States), Series A	Developer of therapeutics to treat cancer and ophthalmological diseases	$20M	Hangzhou Kaitai Capital Management	29/100
9th	Retinset 2014, Barcelona (Spain), Funding Raised	Developer of therapeutics to treat ophthalmological disorders	-	EIC Fund, Europa & 1 others	29/100
10th	Angios 2021, Innsbruck (Austria), Unfunded	Developer of therapeutics for multiple diabetes-related diseases	-	-	27/100
23rd	Semmatx.com 2014, Funding Raised	Developer of stem cell therapies to treat patients with diabetes	-	F-Prime Capital	15/100